摘要
目的从T细胞亚群及细胞因子的角度探究当归芍药散对慢性盆腔炎大鼠模型的作用机制。方法采用混合菌感染合并机械损伤法制备慢性盆腔炎大鼠模型。60只雌性大鼠随机分为正常组,模型组,金刚藤胶囊组,当归芍药散高、中、低剂量组。用药14 d后,观察子宫病理组织改变;流式细胞术测定外周血CD3、CD4、CD8细胞,辅助性淋巴细胞(Th细胞),细胞毒性淋巴细胞(Tc细胞)数量百分比;测定血清中一氧化氮(NO)、白细胞介素(IL)-4、IL-10的含量。结果光学显微镜观察显示,当归芍药散高、中剂量组可以降低大鼠子宫内膜的炎症细胞浸润,促进病变上皮细胞增生修复;当归芍药散高、中剂量组可以显著升高Th细胞、CD3细胞、CD4细胞以及Th/Tc、CD4/CD8比值(P<0.01,P<0.05),降低Tc细胞、CD8细胞(P<0.01,P<0.05);当归芍药散高、中剂量组可以显著升高IL-4、IL-10含量,降低NO含量(P<0.05);与金刚藤胶囊组比较,高剂量组显著升高IL-4含量(P<0.01),降低NO含量(P<0.05)。结论当归芍药散可能通过改善免疫状态,降低炎症反应以发挥治疗慢性盆腔炎的作用。
Objective To explore the therapeutic mechanism of Danggui Shaoyao San（DSS）in treating chronic pelvic inflammatory disease（CPID） through observation of T-cell subsets and cytokines. Methods Rat model of CPID was established by mixed bacterial infection and mechanical damage. Sixty female rats were randomized into normal group,model group,Jingangteng capsule group,and high-,medium-,and low-dose DSS groups. After treatment for 14 days, pathological features of the uterus were observed,the percentage of CD3,CD4,CD8 cells as well as helper T lymphocytes（Th）,cytotoxic T lymphocytes（Tc） in peripheral blood was measured by flow cytometry,and the levels of nitric oxide（NO）, interleukin-4（IL-4） and IL-10 in the blood serum were examined. Results Under light microscope, the inflammatory cell infiltration in the endometrium was reduced and epithelial cell proliferation and recovery were improved in the three DSS groups. High and medium doses of DSS significantly increased the percentages of Th,CD4,and CD3 cells as well as the ratio of Th/Tc,CD4/CD8,and markedly decreased the percentages of Tc,CD8 cells（P0.01,P0.05）. High and medium doses of DSS also increased IL-4,IL-10 expression level,and markedly decreased NO expression level（P0.05）. Compared with Jingangteng capsule group,IL-4 level of rats in high-dose DSS group was increased obviously（P 0.01）, and NO level was decreased dramatically（P 0.05）.Conclusion DSS can improve the immune state and reduce the inflammatory reaction,which may play the major roles in the treatment of CIPD.
出处
《中药新药与临床药理》
CAS
CSCD
北大核心
2016年第4期528-533,共6页
Traditional Chinese Drug Research and Clinical Pharmacology
基金
内蒙古自治区自然科学基金(2014MS0837)
